Low Dose Whole Lung Radiation Therapy for COVID-19 Pneumonia

Single Institutional Pilot Study Of Low Dose Whole Lung Radiation Therapy In Moderate To Severe COVID-19 Pneumonia Patients.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034115

Enrollment

Registered

2021-06-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Low Dose Whole Lung Radiation Therapy: Low Dose Whole Lung Radiation Thearapy, Dose 60cGy in 1Fraction. Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient with informed consent 2. Age >18 yrs and 3. COVID-19 RT-PCR positive 4. RT-PCR done less than 7days 5. Moderate to severe case (NEWS 2 score- more than or equal to 5) 6. SPO2- 24 per minute in Room air 7. KPS >60 8. HRCT suggestive of Interstitial pneumonia with CORADS 4-6 and CT severity score of moderate to severe. 9. Patient able to lie supine for Radiation therapy

Exclusion criteria

Exclusion criteria: 1. Patient on mechanical ventilator support 2. Hemodynamically unstable patient 3. Pregnancy and lactating mothers 4. Known prior systemic use of the following drugs: Bleomycin, Carmustine, Methotrexate, Busulfan,Cyclophosphamide, or Amiodarone 5. History of lung lobectomy or pneumonectomy. 6. History of receiving immunotherapy within the past 6 months. 7. History of Chronic obstructive pulmonary disease, Severe Left Ventricular Dysfunction and patients on beta blockers.

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of Low dose radiation therapy (LDRT) on oxygen dependence in moderate to severe COVID 19 pneumonia with National Early Warning Score(NEWS-2).Timepoint: National Early Warning Score(NEWS-2) on Day 3, Day 7 and Day 14 compared with baseline(Day 0).	—

Secondary

Measure	Time frame
To assess the clinical efficacy of LDRT interms of:- 1. Radiological response using CT Severity Score, 2. Effect on inflammatory markers(CRP, LDH, IL6, D dimer, Ferritin). 3. Length of hospital stay in moderate to severe COVID 19 patients 4. Requirement of ventilator support and ICU admission 5. Acute toxicity assessed with RTOG toxicity grading and CTCAE V.5.0. Timepoint: 1. Radiological response monitored with HRCT at baseline, Day 7 and Day 14 from the day of LDRT. 2. Covid-19 biomarkers- CRP, LDH, IL6, D-dimer, Ferritin levels assessed at baseline, Day 7 and Day 14. 3. Acute Radiation Toxicity assessment done on Day 3, Day 7, Day 14 using RTOG toxicity Grading and CTCAE V.5.0.	—

Measure

Time frame

To assess the clinical efficacy of LDRT interms of:- 1. Radiological response using CT Severity Score, 2. Effect on inflammatory markers(CRP, LDH, IL6, D dimer, Ferritin). 3. Length of hospital stay in moderate to severe COVID 19 patients 4. Requirement of ventilator support and ICU admission 5. Acute toxicity assessed with RTOG toxicity grading and CTCAE V.5.0. Timepoint: 1. Radiological response monitored with HRCT at baseline, Day 7 and Day 14 from the day of LDRT. 2. Covid-19 biomarkers- CRP, LDH, IL6, D-dimer, Ferritin levels assessed at baseline, Day 7 and Day 14. 3. Acute Radiation Toxicity assessment done on Day 3, Day 7, Day 14 using RTOG toxicity Grading and CTCAE V.5.0.

—

Countries

India

Contacts

Public ContactPoornachandra Tejaswi

Karnataka Cancer Therapy And Research Institute

pct.teju@gmail.com8105137717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026